Aurinia Pharmaceuticals (FRA:IKAP) Interest Income : €16.1 Mil (TTM As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Aurinia Pharmaceuticals's interest income for the three months ended in Sep. 2024 was €3.8 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2024 was €16.1 Mil.

Aurinia Pharmaceuticals Interest Income Historical Data

The historical data trend for Aurinia Pharmaceuticals's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Interest Income Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

2.43

1.25

0.47

4.83

15.59

Aurinia Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Income	Get a 7-Day Free Trial															4.23	4.19	4.16	3.89	3.85

Aurinia Pharmaceuticals Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.1 Mil.

Aurinia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

AUPH:USA IKAP:Germany

Address

14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals Headlines

No Headlines